Search: WFRF:(Sjöberg M.)
> (1995-1999) >
Tolerance and effic...
Tolerance and efficacy of Omniscan (gadodiamide injection) in MR imaging of the central nervous system
-
Ekholm, S (author)
-
Jonsson, E (author)
-
Sandvik, L (author)
-
show more...
-
Fagerlund, M (author)
-
- Holtås, Stig (author)
- Lund University,Lunds universitet,Diagnostisk radiologi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Diagnostic Radiology, (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine
-
Isberg, B (author)
-
Lindell, D (author)
-
Linden, B (author)
-
Sjöberg, S (author)
-
Thuomas, K A (author)
-
Tollesson, P O (author)
-
show less...
-
(creator_code:org_t)
- 1996
- 1996
- English.
-
In: Acta Radiologica. - 1600-0455. ; 37:2, s. 223-228
- Related links:
-
https://lup.lub.lu.s...
Abstract
Subject headings
Close
- PURPOSE: This Swedish multicenter trial was performed on patients with known or suspected lesions of the CNS for which an MR examination using a contrast medium was indicated. A total of 8 MR centers participated in the study to establish the safety and efficacy of Omniscan (gadodiamide injection) in clinical routine using a standard dose of 0.1 mmol Gd/kg b.w. MATERIAL AND METHODS: Seven hundred adult patients who had been referred for MR investigation of suspected CNS lesions were included in the study. Since most patients were examined on an outpatient basis, it was decided to use an explicit questionnaire regarding adverse events that developed within 24 h after examination. The efficacy evaluation involved comparisons of detectability, delineation, and number of lesions before and after injection of Omniscan. RESULTS: No serious or unexpected adverse event was found. There were a total of 70 (10.2%) patients with adverse events, excluding those judged not to be contrast media-related. However, only 15 patients (2.2%) had adverse events that possibly or probably were related to the contrast medium. Usually, the symptoms were headache, dizziness, abnormal taste, and nausea. Two patients complained of itching, but only one developed urticaria. The efficacy was similar to that of other currently used Gd-based MR agents. Lesions were more often seen on T2-weighted images, but the contrast medium improved lesion delineation, contributing to higher certainty in diagnosis, and provided more confidence in excluding suspected abnormality. CONCLUSION: Omniscan was found to be a safe and clinically valuable contrast medium for MR imaging of the CNS.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Radiologi och bildbehandling (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Radiology, Nuclear Medicine and Medical Imaging (hsv//eng)
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database
- By the author/editor
-
Ekholm, S
-
Jonsson, E
-
Sandvik, L
-
Fagerlund, M
-
Holtås, Stig
-
Isberg, B
-
show more...
-
Lindell, D
-
Linden, B
-
Sjöberg, S
-
Thuomas, K A
-
Tollesson, P O
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Radiology Nuclea ...
- Articles in the publication
-
Acta Radiologica
- By the university
-
Lund University